ID   NCC-UPS2-C1
AC   CVCL_RP62
SY   NCCUPS2C1
DR   DepMap; ACH-002784
DR   Wikidata; Q54907636
RX   PubMed=29359268;
WW   Provider; BizCom; -; https://en.cellline.jp/product/ncc-ups2-c1/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo, Tadashi).
CC   Doubling time: 45 hours (PubMed=29359268).
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics.
ST   Source(s): PubMed=29359268
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9
ST   D16S539: 10
ST   D21S11: 33.2
ST   D5S818: 10
ST   D7S820: 10,11
ST   TH01: 6
ST   TPOX: 10
ST   vWA: 14
DI   NCIt; C4247; Undifferentiated pleomorphic sarcoma
DI   ORDO; Orphanet_2023; Undifferentiated pleomorphic sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   84Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 9
//
RX   PubMed=29359268; DOI=10.1007/s11626-018-0229-7;
RA   Oyama R., Kito F., Sakumoto M., Shiozawa K., Toki S., Yoshida A.,
RA   Kawai A., Kondo T.;
RT   "Establishment and proteomic characterization of a novel cell line,
RT   NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic
RT   sarcoma.";
RL   In Vitro Cell. Dev. Biol. Anim. 54:257-263(2018).
//